Download presentation
Presentation is loading. Please wait.
Published byShannon York Modified over 6 years ago
1
Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer
3
Topics of Discussion
4
ABC2/ABC3 Guidelines: Management of Postmenopausal HR-Positive MBC
5
Tamoxifen vs AIs in First-Line HR-Positive MBC
6
FALCON Trial Results Showed Improvement in PFS
8
FALCON Trial PFS: Fulvestrant 500 mg vs Anastrozole
9
Mechanisms of CDK4/6 Inhibition in Breast Cancer
11
First-Line PALOMA-1 Trial: PFS Results
12
First-Line PALOMA-2 Trial: PFS Results
13
First Line MONALEESA-2 Trial: PFS
16
Deciding When to Use CDK4/6 Inhibitors in First-Line Setting
17
Selecting Patients for Palbociclib Based on Visceral Metastases
18
When Should Palbociclib Be Used in Second-Line Setting?
19
Second-Line PALOMA-3 Trial: PFS Results
20
BOLERO-2: Benefit of Adding Everolimus to Exemestane
21
Endocrine Therapy vs Chemotherapy
22
Use of Palbociclib-Based Treatments
23
Recommended Palbociclib Dose Adjustments for Patients With Neutropenia
24
Impact of Quality of Life in Patients Receiving Palbociclib Combination Therapy
25
Concluding Remarks
26
Abbreviations
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.